Page last updated: 2024-12-10
2-thioxo-4-thiazolidinecarboxylic acid
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
2-thioxo-4-thiazolidinecarboxylic acid: in urine of workers exposed to carbon disulfide [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 3034757 |
| CHEBI ID | 166452 |
| SCHEMBL ID | 3892885 |
| MeSH ID | M0099337 |
Synonyms (24)
| Synonym |
|---|
| 2-sulanylidene-1,3-thiazolidine-4-carboxylic acid |
| CHEBI:166452 |
| 20933-67-9 |
| 2-thioxothiazolidine-4-carboxylic acid |
| thiazolidine-2-thione-4-carboxylic acid |
| 2-sulfanylidene-1,3-thiazolidine-4-carboxylic acid |
| AKOS002298899 |
| FT-0675200 |
| 2-thioxo-4-thiazolidinecarboxylic acid |
| 4-thiazolidinecarboxylic acid, 2-thioxo- |
| 2-thiothiazolidine-4-carboxylic acid |
| 2-thiazolidinethione-4-carboxylic acid |
| F3339-0170 |
| AKOS016328777 |
| SCHEMBL3892885 |
| 4-carboxythiazolidine-2-thione |
| 2-thioxo-1,3-thiazolidine-4-carboxylic acid # |
| VU0421976-2 |
| J-013727 |
| 2-mercaptothiazoline-4-carboxylic acid |
| DTXSID20943223 |
| (r)-2-thioxo-4-thiazolidinecarboxylic acid |
| (r)-thiazolidine-2-thione-4-carboxylic acid |
| SB45095 |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " The air concentration at which such adverse effects can first be observed is presently a subject of controversy." | ( Neurotoxicity of long-term low-level exposure to carbon disulphide: results of questionnaire, clinical neurological examination and neuropsychological testing. Angerer, J; Bickel, A; Claus, D; Drexler, H; Lehnert, G; Neundörfer, B; Reinhardt, F; Ulm, K, 1997) | 0.3 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " Analysis of urinary TTCA proved to be useful both for establishing the in vivo release of CS2 by dithiocarbamate containing compounds and for evaluating the bioavailability of CS2." | ( The measurement of 2-thiothiazolidine-4-carboxylic acid as an index of the in vivo release of CS2 by dithiocarbamates. Amarnath, K; Amarnath, V; Graham, DG; Johnson, DJ; Valentine, WM, ) | 0.13 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " After oral dosing (10 mg/rat), PB had an inhibiting effect on the excretion rate of TTCA." | ( Effect of cytochrome P450 isozyme induction and glutathione depletion on the metabolism of CS2 to TTCA in rats. Aitio, A; Elovaara, E; Kivistö, H; Riihimaki, V, 1995) | 0.29 |
| " The results of this preliminary study indicate that analysis of TTCA, although regarded as an established biomarker, can give biases and thus negatively interfere with inferred dose-effect or dose-response relationships in occupational epidemiology." | ( Preliminary external quality assessment for the biological monitoring of carbon disulfide with urinary 2-thiothiazolidine-4-carboxylic acid. Braeckman, L; Bulat, P; Daemen, E; de Bacquer, D; van Risseghem, M; Vanhoorne, M, 1999) | 0.3 |
| " Cardiovascular parameters included blood pressure, total, LDL and HDL cholesterol, triglycerides, C-reactive protein dosed in serum with high sensitivity (HsCRP), N-terminal pro-brain natriuretic peptide, and albuminuria/creatininuria ratio (UACR)." | ( No evidence of cardiovascular toxicity in workers exposed below 5 ppm carbon disulfide. Domergue, J; Haufroid, V; Lison, D, 2016) | 0.43 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (2)
| Class | Description |
|---|---|
| organonitrogen compound | Any heteroorganic entity containing at least one carbon-nitrogen bond. |
| organooxygen compound | An organochalcogen compound containing at least one carbon-oxygen bond. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Bioassays (2)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (62)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 9 (14.52) | 18.7374 |
| 1990's | 23 (37.10) | 18.2507 |
| 2000's | 13 (20.97) | 29.6817 |
| 2010's | 9 (14.52) | 24.3611 |
| 2020's | 8 (12.90) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 10.61
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (10.61) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (1.43%) | 5.53% |
| Reviews | 4 (5.71%) | 6.00% |
| Case Studies | 1 (1.43%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 64 (91.43%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||